Novabay Pharmaceuticals, INC Form 4 insider transactions

Director Julie Garlikov of NovaBay Pharmaceuticals acquired 30,000 restricted stock units on May 28, 2024, according to a recent SEC filing.

Paul E. Freiman, a director of NovaBay Pharmaceuticals, acquired 30,000 restricted stock units on May 28, 2024, according to a recent SEC Form 4 filing.

Director Swan Sit acquired 30,000 restricted stock units in NovaBay Pharmaceuticals, vesting one year from the grant date.

Director Mijia Wu of NovaBay Pharmaceuticals acquired 30,000 restricted stock units on May 28, 2024, which vest one year from the grant date.

Director Yenyou Zheng acquired 30,000 restricted stock units in NovaBay Pharmaceuticals, vesting one year from the grant date.

Director Yongxiang Zheng acquired 30,000 restricted stock units in NovaBay Pharmaceuticals on May 28, 2024, according to a Form 4 filing.